This research, published only as an abstract, evaluated the impact of a pharmacokinetic-guided prophylaxis strategy for hemophilia A patients using the myPKFiTTM tool developed for alfa-octocogTM recombinant FVIII (Advate, Takeda). This evidence concerns the gene F8 and hemophilia A.